Eton Pharmaceuticals (ETON)
Develops and commercializes rare-disease therapies through product launches and rights agreements.
$57.50
After hours+0.35 (+0.61%)
At close$57.15(+3.33%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7 | 7 | 8 | 9 | 10 | 12 | 17 | 19 | 22 | 21 | 24 | 38 |
| Cost of revenue | 3 | 4 | 3 | 3 | 4 | 5 | 7 | 7 | 15 | 8 | 10 | 12 |
| Gross profit | 4 | 4 | 5 | 6 | 6 | 6 | 10 | 12 | 8 | 13 | 15 | 25 |
| 5 | 6 | 6 | 9 | 6 | 6 | 10 | 13 | 9 | 11 | 12 | 13 | |
| Research & development | 1 | 1 | 1 | 3 | 1 | −1 | 1 | 4 | 1 | 2 | 2 | 1 |
| 4 | 5 | 5 | 6 | 5 | 7 | 9 | 10 | 8 | 9 | 10 | 12 | |
| General & administrative | 4 | 5 | 5 | 6 | 5 | 7 | 9 | 10 | 8 | 9 | 10 | 12 |
| Operating income | −1 | −2 | −1 | −3 | 1 | 1 | 0 | −1 | −1 | 2 | 2 | 13 |
| 0 | 0 | 0 | 0 | 0 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | −1 | 1 |
| Other non-operating income | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | −1 | 0 | 2 | 0 |
| Income before tax | −1 | −2 | −1 | −3 | 1 | −1 | −1 | −3 | −2 | 1 | 2 | 12 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −1 | −2 | −1 | −3 | 1 | −1 | −2 | −3 | −2 | 1 | 2 | 12 |
| Net income | −1 | −2 | −1 | −3 | 1 | −1 | −2 | −3 | −2 | 1 | 2 | 12 |
| EPS, basic | −$0.02 | −$0.09 | −$0.03 | −$0.12 | $0.02 | −$0.02 | −$0.06 | −$0.10 | −$0.07 | $0.06 | $0.06 | $0.42 |
| EPS, diluted | −$0.02 | −$0.09 | −$0.03 | −$0.12 | $0.02 | −$0.02 | −$0.06 | −$0.10 | −$0.07 | $0.05 | $0.05 | $0.35 |
| Weighted average shares, basic | 26 | 26 | 26 | 26 | 26 | 26 | 27 | 27 | 27 | 27 | 27 | 28 |
| Weighted average shares, diluted | 26 | 26 | 26 | 26 | 27 | 26 | 27 | 27 | 27 | 27 | 32 | 33 |
| EBITDA | 0 | −3 | −1 | −3 | 1 | 0 | 1 | 0 | 0 | 4 | 2 | 13 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| EBIT | −1 | −3 | −1 | −3 | 1 | −1 | 0 | −1 | −1 | 3 | 1 | 13 |